ContraFect Stock Forecast, Price & News

-0.03 (-0.73 %)
(As of 08/2/2021 11:26 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume207 shs
Average Volume684,110 shs
Market Capitalization$160.87 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

ContraFect logo

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. The company has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. It also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. The company was incorporated in 2008 and is headquartered in Yonkers, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.07 out of 5 stars

Medical Sector

502nd out of 2,221 stocks

Pharmaceutical Preparations Industry

245th out of 869 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ContraFect (NASDAQ:CFRX) Frequently Asked Questions

Is ContraFect a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ContraFect stock.
View analyst ratings for ContraFect
or view top-rated stocks.

What stocks does MarketBeat like better than ContraFect?

Wall Street analysts have given ContraFect a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ContraFect wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ContraFect?

ContraFect saw a drop in short interest in June. As of June 30th, there was short interest totaling 3,420,000 shares, a drop of 27.1% from the June 15th total of 4,690,000 shares. Based on an average trading volume of 434,300 shares, the days-to-cover ratio is currently 7.9 days. Currently, 9.3% of the company's shares are short sold.
View ContraFect's Short Interest

When is ContraFect's next earnings date?

ContraFect is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for ContraFect

How were ContraFect's earnings last quarter?

ContraFect Co. (NASDAQ:CFRX) released its quarterly earnings results on Monday, May, 17th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.22) by $0.04.
View ContraFect's earnings history

How has ContraFect's stock been impacted by COVID-19?

ContraFect's stock was trading at $6.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CFRX stock has decreased by 41.1% and is now trading at $4.10.
View which stocks have been most impacted by COVID-19

When did ContraFect's stock split? How did ContraFect's stock split work?

ContraFect shares reverse split before market open on Tuesday, February 4th 2020. The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 3rd 2020. An investor that had 100 shares of ContraFect stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CFRX?

4 brokers have issued twelve-month price targets for ContraFect's stock. Their forecasts range from $6.50 to $22.00. On average, they anticipate ContraFect's share price to reach $14.00 in the next year. This suggests a possible upside of 241.5% from the stock's current price.
View analysts' price targets for ContraFect
or view top-rated stocks among Wall Street analysts.

Who are ContraFect's key executives?

ContraFect's management team includes the following people:
  • Dr. Roger James Pomerantz FACP, M.D., F.A.C.P., Chairman, CEO & Pres (Age 64, Pay $1.37M)
  • Mr. Michael Messinger CPA, CPA, Chief Financial Officer (Age 46, Pay $623.3k)
  • Dr. Cara M. Cassino, Chief Medical Officer and Exec. VP of R&D (Age 59, Pay $883.15k)
  • Ms. Natalie Bogdanos J.D., Gen. Counsel, Corp. Sec. & Data Protection Officer (Age 52)
  • Dr. Gary Woodnutt, Sr. VP of Translational Sciences & Preclinical Devel. (Age 64)
  • Dr. Michael Wittekind, Consultant (Age 66)

Who are some of ContraFect's key competitors?

What other stocks do shareholders of ContraFect own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX).

What is ContraFect's stock symbol?

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

Who are ContraFect's major shareholders?

ContraFect's stock is owned by a variety of retail and institutional investors. Top institutional investors include Minot Wealth Management LLC (0.18%) and MAI Capital Management (0.03%). Company insiders that own ContraFect stock include Cary Sucoff and Michael Messinger.
View institutional ownership trends for ContraFect

Which institutional investors are selling ContraFect stock?

CFRX stock was sold by a variety of institutional investors in the last quarter, including Minot Wealth Management LLC, and MAI Capital Management.
View insider buying and selling activity for ContraFect
or view top insider-selling stocks.

How do I buy shares of ContraFect?

Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ContraFect's stock price today?

One share of CFRX stock can currently be purchased for approximately $4.10.

How much money does ContraFect make?

ContraFect has a market capitalization of $161.27 million. The biotechnology company earns $-28,160,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis.

How many employees does ContraFect have?

ContraFect employs 33 workers across the globe.

What is ContraFect's official website?

The official website for ContraFect is

Where are ContraFect's headquarters?

ContraFect is headquartered at 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701.

How can I contact ContraFect?

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at (914) 207-2300 or via email at [email protected]

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.